GS II: Government Policies and Interventions for Development in various sectors and Issues arising out of their Design and Implementation
Context: The Health Ministry has banned 16 Fixed Dose Combination (FDC) drugs after scientific review found them irrational, unsafe or lacking therapeutic justification.
- The ban will be effective only if State Drug Controllers, enforcement agencies, manufacturers, distributors and pharmacies strictly stop the sale and stocking of these drugs.
About Fixed Dose Combination Drugs
- Meaning: Fixed Dose Combination (FDC) drugs contain two or more active pharmacological ingredients in a fixed ratio within a single dosage form.
- Purpose: FDCs are intended to reduce pill burden, improve treatment compliance and simplify therapy in chronic conditions such as Tuberculosis.
- Rational Use: FDCs are useful only when the combination has clear therapeutic value, compatible dosing and proven safety.
Best Online Coaching for UPSC
Concerns with Irrational FDCs
- Therapeutic Irrationality: Some FDCs combine drugs without adequate scientific justification, making them ineffective or medically unnecessary.
- Patient Safety Risk: Irrational combinations expose patients to avoidable side effects, allergies and drug interactions.
- Dose Rigidity: Fixed combinations make it difficult to adjust the dose of individual drugs according to patient-specific needs.
- Allergy Detection Problem: If a patient develops an adverse reaction, identifying the responsible ingredient becomes difficult.
- Unnecessary Drug Exposure: Patients may not require all components of an FDC, but still consume multiple drugs due to the fixed formulation.
- AMR Threat: Irrational antibiotic-based FDCs can worsen antimicrobial resistance (AMR) by promoting unnecessary and inappropriate antibiotic use.
Regulatory Background
- 2016 Crackdown: The government had earlier banned over 330 irrational FDCs in March 2016, showing that unsafe combinations have been a recurring regulatory concern.
- Antibiotic Concern: Around 19% of the FDCs banned in 2016 were antibiotic combinations, highlighting the link between irrational FDCs and antimicrobial resistance.
- Evidence-Based Regulation: The recent ban reflects the need for drug regulation to remain responsive to new scientific evidence and emerging public health risks.
Governance Challenges
- Weak Last-Mile Enforcement: Banned drugs may continue to be sold in pharmacies if regulatory instructions do not reach the retail level.
- Stock Clearance Problem: Existing stocks with distributors and pharmacies can remain in circulation without active monitoring and recall.
- Fragmented Oversight: Coordination gaps between central regulators, State Drug Controllers and field inspectors weaken implementation.
- Commercial Pressure: Pharmaceutical companies and sellers may prioritise profit over rational drug use unless penalties are strictly enforced.
Way Forward
- Strict Market Surveillance: Drug inspectors must regularly monitor pharmacies, distributors and hospitals to prevent continued sale of banned FDCs.
- Clear Recall Mechanism: Manufacturers and distributors should be directed to withdraw banned formulations from the supply chain immediately.
- Digital Drug Tracking: India should use digital databases and supply-chain tracking to identify banned formulations and prevent their circulation.
- Prescription Audits: Medical prescriptions should be reviewed periodically to discourage irrational use of FDCs.
- Antibiotic Stewardship: Antibiotic-based FDCs must be regulated strictly to contain antimicrobial resistance.
- Pharmacovigilance: Adverse drug reaction monitoring should be strengthened to identify unsafe combinations early.
- Public Awareness: Patients must be informed not to consume or purchase banned drugs without medical advice.
Click to Explore UPSC Offline Coaching
Conclusion
FDCs can improve compliance when rationally designed, but irrational combinations can harm patients and worsen public health challenges. The ban on 16 FDCs is a positive step, but its success depends on strict monitoring, effective recall and last-mile enforcement.
23 Jun 2026
